Vericel Corp
VCELHealthcare|Biotechnology|USA
$47.00
-1.32 (-2.73%)
DCF (FCF)
$9.33
Tangible Book
$6.88
Graham Number
$8.06
Earnings Power
$1.32
About
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Stock Price
+14.0%(1Y)
Pipeline Summary
15 total trials3
Phase 1
7
Phase 2
5
Phase 3
1
Phase 4
Completed: 11Recruiting: 2Terminated: 2
Active Trials (2)
A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle
NCT06915233Chondral Defect
Phase 3Recruiting
Enrollment: 309 participants
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
NCT03588975Chondral Defect
Phase 3Recruiting
Enrollment: 45 participants
BioScore
6.1/10
Watchlist
Ownership
Recent Insider Trades
SIEGAL JONATHANSELL
2026-06-262,732 shares @ $44.9
Mara Joseph Anthony JrSELL
2026-06-265,000 shares @ $44.75
Hopper Jonathan MarkSELL
2026-06-2610,000 shares @ $45
Flynn Sean C.SELL
2026-06-2615,000 shares @ $45.64
Halpin MichaelSELL
2026-06-1810,000 shares @ $40.24
Data last updated: Jul 13, 2026, 12:42 PM